Filing Flows › TriSalus Life Sciences (TLSI) › Q1 2025
TriSalus Life Sciences (TLSI) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
TriSalus Life Sciences (TLSI) reported revenue of $9.2M for the first quarter 2025 (Q1 2025), +42% from a year earlier and +11% from the quarter before. Operating margin was -79.9%, net loss $10.4M (113.2% of revenue).
TriSalus Life Sciences, Q1 2025: revenue $9.2M (+42% year over year), operating margin -79.9%, net loss $10.4M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.2M | +11% | +42% |
| Operating profit | −$7.3M | — | — |
| Net earnings | −$10.4M | — | — |
| Operating cash flow | −$4.5M | — | — |
What changed
Revenue was $9.2M in Q1 2025, up 42% year over year and up 11% from the previous quarter.
Gross margin was 83.7%, down 1.3 points from a year earlier. Operating costs exceeded revenue by $7.3M, an operating margin of -79.9%. Operating expenses fell 13% while revenue rose 42%. The quarter ended with a net loss of $10.4M, wider than the previous quarter's $10.1M loss.
Operating cash flow was −$4.5M. Non-cash charges added back $172K of depreciation and amortization and $1.6M of share-based compensation. Working capital and other items added $4.1M. Capital expenditures of $754K exceeded it, leaving free cash flow of −$5.3M.
Questions
What was TriSalus Life Sciences' revenue in the first quarter 2025?
TriSalus Life Sciences (TLSI) reported revenue of $9.2M for the first quarter 2025 (Q1 2025), +42% from a year earlier and +11% from the quarter before.
Was TriSalus Life Sciences profitable in the first quarter 2025?
Operating loss was $7.3M (-79.9% of revenue) and net loss $10.4M.